Literature DB >> 18923722

Treatment options for hepatitis B.

Jm Conly1, Bl Johnston.   

Abstract

Entities:  

Year:  2007        PMID: 18923722      PMCID: PMC2533552          DOI: 10.1155/2007/464652

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


× No keyword cloud information.
  18 in total

1.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors:  Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

2.  Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.

Authors:  N C Tassopoulos; R Volpes; G Pastore; J Heathcote; M Buti; R D Goldin; S Hawley; J Barber; L Condreay; D F Gray
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

3.  Lamivudine as initial treatment for chronic hepatitis B in the United States.

Authors:  J L Dienstag; E R Schiff; T L Wright; R P Perrillo; H W Hann; Z Goodman; L Crowther; L D Condreay; M Woessner; M Rubin; N A Brown
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

Review 4.  Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B.

Authors:  Scott K Fung; Anna S F Lok
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2004-12

5.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Jia Ma; Sarah Arterburn; Shelly Xiong; Graeme Currie; Carol L Brosgart
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

6.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

Authors:  C Boni; A Bertoletti; A Penna; A Cavalli; M Pilli; S Urbani; P Scognamiglio; R Boehme; R Panebianco; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

Review 7.  Management of hepatitis B: summary of a clinical research workshop.

Authors:  Jay H Hoofnagle; Edward Doo; T Jake Liang; Russell Fleischer; Anna S F Lok
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

8.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

9.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

Authors:  Ting-Tsung Chang; Robert G Gish; Robert de Man; Adrian Gadano; José Sollano; You-Chen Chao; Anna S Lok; Kwang-Hyub Han; Zachary Goodman; Jin Zhu; Anne Cross; Deborah DeHertogh; Richard Wilber; Richard Colonno; David Apelian
Journal:  N Engl J Med       Date:  2006-03-09       Impact factor: 91.245

10.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Authors:  Ching-Lung Lai; Daniel Shouval; Anna S Lok; Ting-Tsung Chang; Hugo Cheinquer; Zachary Goodman; Deborah DeHertogh; Richard Wilber; Richard C Zink; Anne Cross; Richard Colonno; Lori Fernandes
Journal:  N Engl J Med       Date:  2006-03-09       Impact factor: 91.245

View more
  1 in total

1.  A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance.

Authors:  Hie-Won Hann; Vicki L Gregory; Jonathan S Dixon; Keith F Barker
Journal:  Hepatol Int       Date:  2008-10-21       Impact factor: 6.047

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.